GT199800166A - Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa. - Google Patents

Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.

Info

Publication number
GT199800166A
GT199800166A GT199800166A GT199800166A GT199800166A GT 199800166 A GT199800166 A GT 199800166A GT 199800166 A GT199800166 A GT 199800166A GT 199800166 A GT199800166 A GT 199800166A GT 199800166 A GT199800166 A GT 199800166A
Authority
GT
Guatemala
Prior art keywords
inhibitor
aldosa
combination
hiperia
glucogen
Prior art date
Application number
GT199800166A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GT199800166A publication Critical patent/GT199800166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Noise Elimination (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA COMBINACION FARMACEUTICA DE UN INHIBIDOR DE LA ALDOSA REDUCTASA Y UN INHIBIDOR DE LA GLUCOGENO FOSFORILASA, A EQUIPOS QUE CONTIENEN TALES COMBINACIONES Y AL USO DE TALES COMBINACIONES PARA TRATAR LA DIABETES, HIPERGLUCEMIA, HIPERCOLESTEROLEMIA, HIPERTENSION, HIPERINSULINEMIA, HIPERLIPIDEMIA, ATEROSCLEROSIS E ISQUEMIA DE TEJIDOS EN LOS MAMIFEROS.
GT199800166A 1997-11-21 1998-10-27 Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa. GT199800166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
GT199800166A true GT199800166A (es) 2000-04-19

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199800166A GT199800166A (es) 1997-11-21 1998-10-27 Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.

Country Status (38)

Country Link
EP (1) EP1032424B9 (es)
JP (1) JP2002504478A (es)
KR (2) KR20010032304A (es)
CN (1) CN1279617A (es)
AP (1) AP911A (es)
AR (1) AR016423A1 (es)
AT (1) ATE205403T1 (es)
AU (1) AU733304B2 (es)
BG (1) BG104435A (es)
BR (1) BR9814698A (es)
CA (1) CA2310069A1 (es)
DE (1) DE69801680T2 (es)
DK (1) DK1032424T3 (es)
DZ (1) DZ2656A1 (es)
EA (1) EA002365B1 (es)
ES (1) ES2161548T3 (es)
GR (1) GR3037071T3 (es)
GT (1) GT199800166A (es)
HR (1) HRP20000327A2 (es)
HU (1) HUP0100272A3 (es)
ID (1) ID24524A (es)
IL (1) IL135713A0 (es)
IS (1) IS5453A (es)
MA (1) MA26568A1 (es)
NO (1) NO20002164L (es)
OA (1) OA11379A (es)
PA (1) PA8462301A1 (es)
PE (1) PE135399A1 (es)
PL (1) PL340643A1 (es)
PT (1) PT1032424E (es)
SK (1) SK7222000A3 (es)
TN (1) TNSN98211A1 (es)
TR (1) TR200001451T2 (es)
UA (1) UA57811C2 (es)
UY (1) UY25258A1 (es)
WO (1) WO1999026659A1 (es)
YU (1) YU30700A (es)
ZA (1) ZA9810636B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047206A1 (en) * 1999-02-12 2000-08-17 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
PT1689757E (pt) 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Compostos heterocíclicos de ácido borónico
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PT2173737E (pt) 2007-07-17 2012-03-19 Bristol Myers Squibb Co Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
EA201270755A1 (ru) 2010-04-08 2013-03-29 Бристол-Майерс Сквибб Компани Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
ATE205477T1 (de) * 1995-06-06 2001-09-15 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren

Also Published As

Publication number Publication date
KR20010032304A (ko) 2001-04-16
YU30700A (sh) 2002-12-10
PE135399A1 (es) 2000-01-15
DE69801680D1 (de) 2001-10-18
TNSN98211A1 (fr) 2005-03-15
DK1032424T3 (da) 2001-11-19
KR100661214B1 (ko) 2006-12-26
SK7222000A3 (en) 2001-09-11
CN1279617A (zh) 2001-01-10
AR016423A1 (es) 2001-07-04
BG104435A (bg) 2001-01-31
AP911A (en) 2000-12-07
AU9555898A (en) 1999-06-15
EA200000433A1 (ru) 2000-12-25
EP1032424A1 (en) 2000-09-06
UY25258A1 (es) 2000-12-29
AU733304B2 (en) 2001-05-10
KR20010032300A (ko) 2001-04-16
EA002365B1 (ru) 2002-04-25
ID24524A (id) 2000-07-20
ATE205403T1 (de) 2001-09-15
BR9814698A (pt) 2000-10-03
ES2161548T3 (es) 2001-12-01
ZA9810636B (en) 2000-05-22
IL135713A0 (en) 2001-05-20
PA8462301A1 (es) 2000-05-24
OA11379A (en) 2004-01-28
NO20002164L (no) 2000-07-19
GR3037071T3 (en) 2002-01-31
NO20002164D0 (no) 2000-04-27
AP9801401A0 (en) 1998-12-31
PL340643A1 (en) 2001-02-12
HRP20000327A2 (en) 2001-02-28
TR200001451T2 (tr) 2002-06-21
MA26568A1 (fr) 2004-12-20
JP2002504478A (ja) 2002-02-12
IS5453A (is) 2000-04-14
WO1999026659A1 (en) 1999-06-03
HUP0100272A3 (en) 2002-11-28
DE69801680T2 (de) 2002-02-07
HUP0100272A2 (hu) 2001-06-28
EP1032424B1 (en) 2001-09-12
PT1032424E (pt) 2001-12-28
DZ2656A1 (fr) 2003-03-22
UA57811C2 (uk) 2003-07-15
EP1032424B9 (en) 2004-10-06
CA2310069A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
GT199800166A (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
ES2178298T3 (es) Compuestos anti-inflamatorios.
PA8521701A1 (es) Derivados de pirazol
ES2140361T1 (es) Composiciones a base de isocianato, su procedimiento de utilizacion, su utilizacion para la obtencion de revestimientos y revestimientos obtenidos de esta manera.
BR9908020A (pt) Fórmula para polimento ótico
ES2119580T3 (es) Composicion cosmetica para aplicar particularmente sobre los labios y utilizaciones.
SV2002000049A (es) Uso de inhibidores de cyp2d6 en combinacion con terapias. ref. pc1044 arfw/bb
BR0104023B1 (pt) aplicador para a aplicação de um produto sobre as fibras queratìnicas e conjunto de aplicação dotado desse aplicador.
BR9913761B1 (pt) uso de uma composiÇço para proteÇço de tecidos.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR015379A1 (es) Ascorbil-fosforil-colesterol
DE19880965T1 (de) Strahlungshärtbare Cyanoacrylat-enthaltende Zusammensetzung
AR010346A1 (es) COMPUESTOS DERIVADOS DE BENZOFURANO; SUS USOS, Y COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE.
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
HN1998000166A (es) Compuesto de benceno sustituido procedimiento para su preparacion y composiciones herbicidas y defoliantes que los contienen.
CL2004001102A1 (es) Compuestos derivados de 2-amino-4-bicicloamino-1,3,5-triazinas; composicion herbicida que los contiene; procedimiento de preparacion; uso de dichos compuestos; y compuestos intermediarios.
CY1105009T1 (el) Συνθεση καχαλαλιδης f
ES2172748T3 (es) Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco.
SV1998000146A (es) Combinaciones de estatina.eter carboxialquilico
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
ES2156640T3 (es) Aglutinante para proyeccion y su empleo.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
PT1007109E (pt) Adesivo para tecidos a base de fibrinogenio
GT199900202A (es) Derivados de indol.
CO4600682A1 (es) Protrombinas como antidoto para los inhibidores de la trom- bina